Compare Abeona Therapeutics Inc (ABEO) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SkyWest Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while SkyWest Inc trades at $96.72 (market cap $3.88B). The key difference: SkyWest Inc is far larger — about 10.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SKYW | |
|---|---|---|
Market Cap | $373.32M | $3.88B |
Sector | Health | Technology |
52-Week High | $7.23 | $123.72 |
52-Week Low | $4.17 | $78.40 |
Enterprise Value | $228.22M | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SkyWest (SKYW) trades at $98.75, up 1.93% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 9.47 and P/S of 0.99, while maintaining strong profitability with 10.42% net margin and 16.5% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains stable revenue around $4.1B with consistent cash flow generation from operations exceeding $900M annually.
The outlook remains positive with 56% analyst buy ratings and $109.33 consensus price target suggesting 11% upside. Key risks include rising fuel costs impacting airline profitability and negative net cash flow trends. The upcoming Q2 2026 earnings call on July 23 will be crucial for confirming growth trajectory amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
